← Back to Search

Procedure

TorEx Lung Perfusion System for Lung Transplant

N/A
Waitlist Available
Led By Laura Donahoe, MD MSc FRCSC
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year post-transplant
Awards & highlights

Summary

This trial aims to improve lung transplantation outcomes by determining the safety and efficacy of the TorEx Lung Perfusion system for assessing donor lungs.

Who is the study for?
This trial is for individuals actively listed for a primary lung transplant, aged between 18 and 70. It's suitable if the donor lungs need extra evaluation to determine their fitness for transplantation. Candidates must consent in writing and cannot be part of another interventional trial or require multi-organ transplantation.Check my eligibility
What is being tested?
The TorEx Lung Perfusion System is being tested on up to 20 patients to see if it's safe and effective compared to the first generation Toronto EVLP system. This new system aims to better assess donor lungs that might otherwise be discarded.See study design
What are the potential side effects?
Since this study focuses on equipment rather than medication, side effects are related to potential complications from using assessed donor lungs in transplants, which may include typical transplant-related risks such as organ rejection or infection.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year post-transplant
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year post-transplant for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of ISHLT Primary Graft Dysfunction Grade 3
Secondary outcome measures
Forced expiratory volume - one second (FEV1 in L)
ICU and hospital length of stay
Occurrence of acute rejection
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Donor lungs assessed using TorEx Lung Perfusion SystemExperimental Treatment1 Intervention

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Ex Vivo Lung Perfusion (EVLP) involves maintaining donor lungs in near-physiological conditions outside the body to assess and improve their function before transplantation. The primary treatments include perfusion with a specialized solution to provide nutrients and remove waste, and ventilation to mimic breathing. These treatments help reduce lung injury, improve oxygenation, and allow for better evaluation of lung viability. The TorEx Lung Perfusion System optimizes this process by integrating all necessary equipment and controls, enhancing the ability to recover and utilize donor lungs that might otherwise be discarded. This is crucial for increasing the availability of suitable lungs for transplantation, thereby reducing wait times and improving patient outcomes.

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,492 Previous Clinical Trials
490,024 Total Patients Enrolled
Laura Donahoe, MD MSc FRCSCPrincipal InvestigatorUniversity Health Network, Toronto

Media Library

TorEx Lung Perfusion System (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05656404 — N/A
Ex Vivo Lung Perfusion Research Study Groups: Donor lungs assessed using TorEx Lung Perfusion System
Ex Vivo Lung Perfusion Clinical Trial 2023: TorEx Lung Perfusion System Highlights & Side Effects. Trial Name: NCT05656404 — N/A
TorEx Lung Perfusion System (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05656404 — N/A
~8 spots leftby Jul 2025